What is the recommended dose of CBD (Cannabidiol) — Full Monograph?

- **Look for:** Third-party COA (Certificate of Analysis); CBD content per serving quantified in mg; THC content <0.3% confirmed; full-spectrum or broad-spectrum specified; USDA organic; GMP certif...

Is CBD (Cannabidiol) — Full Monograph safe to take daily?

CBD (Cannabidiol) — Full Monograph is rated "Generally Safe" based on clinical evidence. Always consult your healthcare provider before starting any supplement.

LOADINGLoading your Pro surface...

Ingredient Research

Graded against 173,636 supplements + 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, NIH DSLD

CBD (Cannabidiol) — Full Monograph

MODERATE EVIDENCESupplementLast updated

AVELOR SUMMARY

CBD (cannabidiol) is a non-intoxicating cannabinoid with FDA-approved use (Epidiolex) for severe epilepsy and moderate evidence for anxiety reduction. Our research shows the clinical evidence is MUCH thinner than the marketing suggests: the strongest evidence is for Dravet/Lennox-Gastaut syndrome epilepsy (FDA-approved), followed by a single acute anxiety study (300mg reduced social anxiety). For chronic pain, sleep, and general "wellness" — the claims massively outpace the evidence. The BIGGEST concern: CBD is a potent CYP3A4 and CYP2C19 inhibitor, meaning it interacts with ~60% of prescription drugs. And the supplement market is a disaster — 28% of products contained less CBD than labeled, 21% contained THC above legal limits.

WHAT IT DOES

CBD's pharmacology is complex and NOT primarily mediated through cannabinoid receptors: (1) 5-HT1A partial agonist — the serotonin receptor responsible for CBD's anxiolytic effects (same receptor targeted by buspirone); (2) TRPV1 agonist — vanilloid receptor activation, desensitization → pain modulation; (3) GPR55 antagonist — orphan cannabinoid receptor involved in cancer cell proliferation; (4) Allosteric modulator of CB1 — does NOT directly activate CB1 (that's THC) but modulates its signaling; (5) Adenosine reuptake inhibition — increases extracellular adenosine (anti-inflammatory, neuroprotective); (6) PPARγ agonist — nuclear receptor activation for anti-inflammatory effects; (7) CYP3A4 and CYP2C19 inhibition — MAJOR drug interaction mechanism.

OPTIMAL DOSAGE

Look for: Third-party COA (Certificate of Analysis); CBD content per serving quantified in mg; THC content <0.3% confirmed; full-spectrum or broad-spectrum specified; USDA organic; GMP certified
Avoid: Products without COA; products claiming to cure/treat diseases (illegal per FDA); isolate-only at low doses; products from untested sources
Minimum effective dose: Anxiety: 300mg (acute). General: 25-50mg/day (poorly standardized)
Third-party tested brands: Charlotte's Web, Lazarus Naturals, CBDistillery, RE Botanicals

Scan a supplement containing CBD (Cannabidiol) — Full Monograph

SAFETY PROFILE

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

RELATED RESEARCH

Acacia Fiber

Activated Charcoal

Agave Inulin

Agmatine SulfateReduced neuropathic pain by 46.1%

Quality Testing Intelligence

Based on independent third-party laboratory analysis

Category pass rate: ~80% for CBD content. THC contamination is the key risk — 1 in 7 "full spectrum" users fail drug tests.

Common failures:

THC contamination: "Full spectrum" products contain enough THC to fail drug tests

Price gouging: 17x price difference between brands for identical 10mg CBD ($0.12 to $2.09)

Hemp seed oil confusion: Often sold as "CBD" but contains zero CBD

Scan Your CBD (Cannabidiol) — Full Monograph Supplement Browse all ingredients

Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:

Not medical advice. Based on published clinical research and systematic reviews.

Discover More

Explore

Browse All 834 Ingredients Browse All 20 Conditions